Belgium

Argenx BVBA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Belgium Belgium

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Argenx Reports Positive Data of Efgartigimod in Myasthenia Gravis Trial

Lead Product(s): Efgartigimod

Therapeutic Area: Immunology Product Name: ARGX-113

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2021

Details:

Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Efgartigimod is currently under review with the FDA for the treatment of gMG.

Galapagos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Galapagos to Present Data on Rheumatoid Arthritis at the Upcoming European League Against Rheumatism (EULAR) Congress

Lead Product(s): Filgotinib

Therapeutic Area: Immunology Product Name: Jyseleca

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2021

Details:

New data analyses on the safety profile of filgotinib, an oral, once-daily, JAK1 preferential inhibitor for the treatment of moderately to severely active RA, are presented from seven trials.